Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Non Operating Income (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Non Operating Income data on record, last reported at -$12.5 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 360.45% year-over-year to -$12.5 million; the TTM value through Sep 2025 reached -$2.0 million, down 111.96%, while the annual FY2024 figure was $20.2 million, 5020.05% up from the prior year.
  • Non Operating Income reached -$12.5 million in Q3 2025 per BTAI's latest filing, down from $657000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $12.0 million in Q2 2024 and bottomed at -$12.5 million in Q3 2025.
  • Average Non Operating Income over 4 years is $1.3 million, with a median of $322500.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: surged 96440.0% in 2024, then crashed 360.45% in 2025.
  • A 4-year view of Non Operating Income shows it stood at $62000.0 in 2022, then surged by 74.19% to $108000.0 in 2023, then skyrocketed by 2953.7% to $3.3 million in 2024, then crashed by 480.41% to -$12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$12.5 million in Q3 2025, $657000.0 in Q2 2025, and $6.6 million in Q1 2025.